Overview

First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-in-human study is to assess the local ocular and systemic safety and tolerability of LHA510 eye drops when administered at various concentrations and dosing frequencies.
Phase:
Phase 1
Details
Lead Sponsor:
Alcon Research
Treatments:
Acrizanib